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Abstract: Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor 
ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of 
a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with 
ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, 
and trastuzumab were reported early based on superiority of the combination in prolonging time 
to tumor progression (TTP). An updated analysis in 399 women supports the earlier ﬁ  ndings. In 
this updated analysis, TTP (hazard ratio [HR] 0.57) favored lapatinib plus capecitabine. Survival 
trended in favor of the combination. The incidence of cardiac events was numerically higher in 
the combination arm (5 cases in the combination arm, 2 cases in the monotherapy arm).
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Introduction
Despite substantial advances in the treatment of breast cancer, it remains the most 
common cause of death in women 45–55 years old (American Cancer Society 2007). 
While only 10% of cases are advanced at the time of diagnosis, after primary treatment 
with curative intent, 10%–20% of patients will have local recurrence within 9 years, 
and 10%–25% will have locally extensive or metastatic disease (Heimann and Hellman 
2000; ESMO Guidelines Working Group 2007).
Treatment of advanced disease is guided in large part by hormone-receptor status, 
ErbB2 (HER2) status, response to prior treatment, and co-existing conditions (eg, 
heart disease) that may or may not be related to prior therapy (eg, anthracyclines and 
trastuzumab).
Approximately 20%–25% of breast cancers overexpress human epidermal recep-
tor type 2 (ErbB2 or HER2), which is associated with a more aggressive cancer 
and predicts poor clinical outcome (Slamon et al 1987). Currently, women with 
ErbB2-positive disease are treated with trastuzumab with or without chemotherapy 
(National Comprehensive Cancer Network 2007), but the optimal duration of treat-
ment remains to be determined. For example, many patients who progress during or 
after trastuzumab-based therapy continue to receive trastuzumab but in combination 
with another chemotherapy, an approach not yet demonstrated effective in randomized 
trials (Hortobogyi 2005; Montemurro et al 2006). With trastuzumab now incorporated 
into the adjuvant setting, it is increasingly important to identify effective management 
strategies for patients who fail to respond to or relapse after receiving it.
Lapatinib (Tykerb®/Tyverb®, GlaxoSmithKline, Research Triangle Park, NC, 
USA), a small molecule inhibitor of tyrosine kinase domains of epidermal growth 
factor receptor (EGFR or ErbB1) and the ErbB2 (HER2) receptor, inhibits ErbB-driven Biologics: Targets & Therapy 2008:2(1) 62
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cell growth (Rusnak et al 2001). Lapatinib binds to the 
ATP-binding site of tyrosine kinase, blocking phosphory-
lation and activation of the receptor. As a result, activation 
of extracellular signal-related kinase (ERK)-1/2 and phos-
phatidylinositol 3′ kinase (PI3K)/Akt is blocked (Rusnak 
et al 2001). In preclinical studies, lapatinib was active 
against trastuzumab-resistant breast cancer cells (Konecny 
et al 2006). In a phase I study, lapatinib was active and 
well tolerated in women with advanced solid tumors when 
administered in combination with capecitabine at the opti-
mally tolerated dose of lapatinib 1250 mg orally Days 1–21 
and capecitabine 2000 mg/m2 Days 1–14 of a 21-day cycle 
(Schwartz et al 2004). Lapatinib monotherapy has been well 
tolerated by women with advanced breast cancer in phase 
II trials (Burstein et al 2004; Blackwell et al 2005; Gomez 
et al 2006). The response rate was highest in the ﬁ  rst-line 
setting (24%), but responses to monotherapy were also seen 
in heavily pretreated patients, including those previously 
treated with trastuzumab (4%–8%). Although lapatinib 
targets two distinct receptor pathways, responses in these 
trials were limited to patients with ErbB2-positive disease.
Lapatinib plus capecitabine for 
ErbB2-positive advanced breast 
cancer
A phase III randomized, open-label study was conducted 
comparing lapatinib plus capecitabine with capecitabine 
monotherapy in women with ErbB2-positive (3+ by immu-
nohistochemistry [IHC] or IHC 2+ and gene ampliﬁ  cation by 
ﬂ  uorescence in situ hybridization [FISH]), locally advanced 
or metastatic breast cancer. Enrollment required that women 
received prior treatment that included, but was not limited to, 
an anthracycline, a taxane, and trastuzumab. In the combina-
tion therapy arm, lapatinib was administered continuously 
at a dose of 1250 mg once daily orally and capecitabine 
2000 mg/m2 in 2 divided doses on Days 1 through 14. In the 
monotherapy arm, capecitabine was administered at a dose 
of 2500 mg/m2 daily in 2 divided doses on Days 1 through 
14. In both arms, treatment was administered on a 21-day 
cycle. The primary endpoint was time to tumor progression 
(TTP) (Geyer et al 2006).
Median age was 53 years and 14% of women were 65 
years old. Approximately half of the women’s tumors were 
hormone receptor positive and nearly all (96%) had meta-
static disease, with approximately 50% having metastases to 
three or more sites. Prior trastuzumab treatment was admin-
istered in the metastatic setting in 95% of patients (Geyer 
et al 2006; Tykerb 2007).
Planned interim analysis
Study enrollment was stopped early based on a planned 
interim analysis of TTP that met criteria for early reporting 
based on superiority in the capecitabine plus lapatinib arm. 
At the time of this analysis a total of 324 women had been 
randomized and there were 49 TTP events in the combination 
therapy arm and 72 in the monotherapy arm, with a hazard 
ratio for TTP of 0.49 (95% CI, 0.34 to 0.71; p  0.001) 
based on an evaluation by blinded independent reviewers.
The median TTP in the combination arm was 8.4 months and 
4.4 months in the monotherapy arm (Geyer et al 2006).
Updated analysis
By the time enrollment was suspended, an additional 75 women 
had been enrolled in the study. An updated analysis was con-
ducted on this larger population of 399 women. With a total of 
82 TTP events in the combination arm and 102 in the mono-
therapy arm by independent review, the hazard ratio for TTP 
remained statistically signiﬁ  cant in favor of capecitabine plus 
lapatinib (HR, 0.57; 95% CI, 0.43–0.77; p = 0.00013). This 
corresponds to an increase in median TTP from 4.3 months 
in the monotherapy group to 6.2 months in the combination 
therapy group (Figure 1A). Overall response rate also favored 
capecitabine plus lapatinib (24% vs 14%), and fewer patients 
treated with the combination developed symptomatic central 
nervous system progression (4 vs 13 patients; p = 0.045 by 
Fisher’s exact test) (Cameron et al 2007; Tykerb 2007).
Thirty percent of patients had died by the time of the 
updated analysis. While overall survival trended in favor of 
capecitabine plus lapatinib, data were not statistically signiﬁ  -
cant (HR, 0.78; 95% CI, 0.55–1.12. p = 0.177) (Figure 1B) 
(Cameron et al 2007; Tykerb 2007).
Safety
The most common adverse events were diarrhea, palmar-
plantar erythrodysesthesia (PPE), nausea, vomiting, and rash 
distinct from PPE (Table 1). The incidence of these adverse 
events was similar in each group, with the exception of diar-
rhea and rash, both more common in women treated with 
capecitabine plus lapatinib. A similar percentage of women 
in each group (14% in the combination group and 14% with 
capecitabine alone) discontinued treatment due to adverse 
events (Tykerb 2007).
Based on experience with trastuzumab, cardiac events were 
closely monitored. A cardiac event was deﬁ  ned as any decline 
in left ventricular ejection fraction (LVEF) that was symp-
tomatic (ie, National Cancer Institute Common Terminology 
Criteria for Adverse Events [NCI CTCAE]  Grade 3)Biologics: Targets & Therapy 2008:2(1) 63
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or an asymptomatic decline that was 20% relative to 
baseline and below the institution’s lower limit of normal. 
There were no differences in the mean LVEF between the 
two treatment groups (Geyer et al 2006). Four asymptomatic 
cardiac events of LVEF occurred in patients treated with the 
combination and two in the monotherapy group. One patient 
in the combination group experienced Prinzmetal’s angina, 
which resolved when treatment was stopped. This patient 
experienced a decrease in LVEF 28 days after stopping treat-
ment with lapatinib. On follow-up, LVEF was at or above 
the lower limit of normal in all patients experiencing cardiac 
events (Geyer et al 2006; Tykerb 2007).
Initial biomarker data
Preliminary results from a biomarker companion study to 
the lapatinib combination trial have recently been reported 
(Cameron et al 2007). The objectives of this study were to 
evaluate correlations between biomarker expression and 
clinical endpoints (TTP/progression-free survival [PFS]) 
and to characterize the biomarker predictors of beneﬁ  t from 
lapatinib. Levels of EGFR/HER2 were analyzed using both 
IHC/FISH and ECD assays. Baseline EGFR/ECD levels 
did not affect PFS in either the combination (p = 0.88) or 
monotherapy arms (p = 0.32). Higher HER2 ECD levels, 
however, were associated with shorter PFS in the capecitabine 
monotherapy group (p = 0.026). This was not demonstrated in 
the lapatinib arm (p = 0.14). When PFS was evaluated with 
respect to baseline HER2 by ECD, the addition of lapatinib 
had a positive effect. This effect was seen regardless of ECD 
level, with a hazard ratio for patients with baseline ECD 78 
of 0.271 (p = 0.0013; 95% CI 0.122, 0.621) and with base-
line ECD 78 of 0.483 (p = 0.0018; 95% CI 0.306, 0.763). 
Table 1 Most frequent adverse events based on National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 3 (Tykerb 2007)
Adverse event  Capecitabine + lapatiniba   Capecitabineb
 (n  = 198)      (n = 191)
  All grades, %  Grade 3, %  Grade 4, %  All grades, %  Grade 3, %  Grade 4, %
Diarrhea 65 13  1  40 10  0
PPE 53  12  0  51  14  0
Rash  28  2 0 14  1 0
Nausea  44  2 0 43  2 0
Vomiting  26  2 0 21  2 0
Mucosal inﬂ   ammation  15  0 0 12  2 0
aLapatinib 1250 mg once daily orally (continuously) and capecitabine 2000 mg/m2 in two divided doses (Days 1 through 14) of a 21-day cycle.
bCapecitabine 2500 mg/m2 in 2 divided doses (Days 1 through 14) of a 21-day cycle.
Abbreviations: PPE, palmar plantar erythrodysesthesia.
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Figure 1 Kaplan-Meier estimates of time to progression (HR 0.57; 95% CI 0.43 to 0.77) p = 0.00013) (A) and overall survival (B) in ITT population and based on indepen-
dent review. Reproduced Cameron D, Martin A-M, Newstat B, et al. 2007. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): updated efﬁ  cacy and 
biomarker analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I, 25:1035.Biologics: Targets & Therapy 2008:2(1) 64
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The biomarker studies are ongoing and include evaluations 
of the entire HER2 family, ﬂ  uoropyrimidine pathway, and 
identiﬁ  cation of potential markers of resistance.
Discussion
Although metastatic breast cancer (MBC) is incurable, 
new treatment strategies now allow it to be managed as a 
chronic disease. Women with MBC are typically treated 
with sequential regimens. When the ﬁ  rst is no longer effec-
tive, a second regimen is tried, and then a third (National 
Comprehensive Cancer Network 2007). This approach might 
result in extended survival. To date, trastuzumab has been 
considered the single most effective treatment for women 
with ErbB2-overexpressing breast cancer. However, contro-
versy exists regarding the optimal duration of treatment and 
the utility of re-treatment after progression. Results from 
the recently closed S0347 trial conducted by the Southwest 
Oncology Group, as well as other on-going phase III trials, 
will provide important information about the appropriateness 
of trastuzumab continuation with alternate chemotherapy 
upon disease progression. Regardless of the outcome of 
these studies, however, there is a need for alternative treat-
ment options.
Lapatinib plus capecitabine offers a new option for 
the treatment of women with ErbB2-positive MBC whose 
disease has progressed following trastuzumab. The addition 
of lapatinib to capecitabine signiﬁ  cantly prolongs TTP, is 
associated with a trend toward improved survival, and offers 
the convenience of oral administration. Consistent with ear-
lier results suggesting that lapatinib crosses the blood-brain 
barrier, (Lin et al 2007), the incidence of symptomatic brain 
metastases as a ﬁ  rst site of progression was signiﬁ  cantly 
reduced when lapatinib was added to capecitabine therapy. 
Because ErbB2-overexpressing breast cancer appears to 
be associated with an increased risk of developing brain 
metastases (Altaha et al 2004) and because trastuzumab 
Table 2 On-going randomized phase III trials of lapatinib in patients with breast cancer
Study Patient population Randomization
EGF104900 Trastuzumab-refractory MBC Lapatinib + trastuzumab
Lapatinib monotherapy
EGF30001 1st-line treatment of ErbB2-negative or untested 
MBC
Lapatinib + paclitaxel
Paclitaxel + placebo
EGF104535 1st-line treatment of ErbB2-overexpressing MBC Lapatinib + paclitaxel
Paclitaxel + placebo
EGF104383 1st-line treatment of ErbB2-overexpressing MBC Lapatinib + paclitaxel + trastuzumab
Placebo + paclitaxel + trastuzumab
EGF108919 1st-line treatment of ErbB2-overexpressing MBC Lapatinib + taxane
Trastuzumab + taxane
EGF30008 1st-line treatment of HR+ advanced breast 
cancer (postmenopausal patients only)
Lapatinib + letrozole
Letrozole + placebo
CALGB 40302 1st-line treatment of HR+ advanced breast 
cancer (postmenopausal patients only)
Lapatinib + fulvestrant
Placebo + fulvestrant
EGF105484 (TEACH) Trastuzumab-naïve patients with ErbB2-
overexpressing ESBC who have completed 
adjuvant chemotherapy
Lapatinib
Placebo
EGF105485 (ALTTO) Adjuvant treatment of ErbB2-overexpressing 
ESBC
Lapatinib
Trastuzumab
Concurrent trastuzumab/lapatinib
Sequential trastuzumab/lapatinib
EGF106903 (Neo-ALTTO) Neoadjuvant treatment of ErbB2-overexpressing 
ESBC
Lapatinib
Trastuzumab
Concurrent trastuzumab/lapatinib
NSABP B-41 Neoadjuvant treatment of ErbB2-overexpressing 
ESBC
Lapatinib
Trastuzumab
Concurrent trastuzumab/lapatinib
Abbreviations: ALTTO, Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization; CALGB, Cancer and Leukemia Group B; ESBC, early stage breast cancer; DFS, 
disease-free survival; HR+, hormone-receptor positive; MBC, metastatic breast cancer; NSABP, National Surgical Adjuvant Breast and Bowel Project; TEACH, Tykerb 
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does not appear to cross the blood-brain barrier (Clayton 
et al 2004; Stemmler et al 2006) this clinically signiﬁ  cant 
ﬁ  nding deserves further study.
Trastuzumab is associated with an increased risk of 
cardiotoxicity, particularly when co-administered with 
anthracyclines (Seidman et al 2002). Many women with 
advanced breast cancer will have received anthracyclines and 
trastuzumab. While lapatinib is not free of cardiac effects, 
the risk appears to be low. In an analysis of cardiac safety 
in 3127 patients treated with lapatinib in clinical trials, the 
incidence of lapatinib-associated asymptomatic LVEF 
decreases was 1.3%. Symptomatic decreases were rare and 
generally reversible (Perez et al 2006).
The combination of lapatinib and capecitabine ﬁ  lls a 
void in the treatment of women with ErbB2-overexpressing 
advanced breast cancer who have received prior therapy 
with an anthracycline, a taxane, and trastuzumab. Ongo-
ing research is investigating the use of lapatinib alone, in 
combination with various cytoxic and biologic agents, in 
combination with trastuzumab, and in adjuvant therapy for 
early breast cancer (Table 2).
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